Research
Molecular
Pharmacological interventions may attenuate the metabolic and inflammatory changes seen in EAT.
These pharmacological options may be considered in managing EAT-related cardiac dysfunction.
StrongSupportsmedium confidence
Pharmacological interventions, including glucagon-like peptide 1 receptor agonists and sodium-dependent glucose linked transporter 2 inhibitors have shown promise in attenuating the deleterious metabolic and inflammatory changes seen in EAT.
Why this rating
The claim is based on ongoing clinical studies and established pharmacological effects.
Source
Epicardial adipose tissue in obesity-related cardiac dysfunction
Sarah L Ayton et al. · Heart · 2021
otherCited 46×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →